Skip to content

Differences in therapeutic effects and myokine regulatory effects of different types of exercise therapy on patients with non-alcoholic fatty liver disease

Differences in therapeutic effects and myokine regulatory effects of different types of exercise therapy on patients with non-alcoholic fatty liver disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117645
Enrollment
Unknown
Registered
2026-01-27
Start date
2026-01-27
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver disease

Interventions

High-Intensity Interval Training Group:The exercise protocol of HIIT is designed with reference to the FITT Principle proposed by the American College of Sports Medicine (ACSM). It involves three trai
this phase consists of three sets of 4-minute cycling bouts, with 2 minutes of active recovery at 50% HRR between sets, and the total duration of this phase is 15–20 minutes. The third is the cool-dow
Moderate-Intensity Continuous Training Group:The weekly exercise volume of MICT is set at 750 MET-min/wk. The exercise protocol is designed with reference to the FITT Principle proposed by the America

Sponsors

Beijing Sport University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 69 Years

Inclusion criteria

Inclusion criteria: 1. Aged 40–69 years; 2. Sedentary lifestyle, defined as less than 90 minutes of physical activity per week; 3. Obesity, defined as a body mass index (BMI) >= 30 kg/m²; 4. MRI-proton density fat fraction (MRI-PDFF) >= 5%.

Exclusion criteria

Exclusion criteria: 1. Presence of unstable cardiovascular disease symptoms; 2. Excessive alcohol consumption (men > 30 g/day, women > 20 g/day, or AUDIT-C score >= 4); 3. Diagnosis of type 2 diabetes mellitus; 4. Presence of other liver diseases (e.g., viral hepatitis); 5. history of cancer; 6. Recent significant weight fluctuations; 7. Inability or unwillingness to provide written informed consent; 8. Any other condition deemed by the investigators to make participation in the study unsuitable.

Design outcomes

Primary

MeasureTime frame
Intrahepatic triglyceride;Thigh Skeletal Muscle Volume;

Secondary

MeasureTime frame
Fibroblast Growth Factor 21;Myostatin;Irisin;Fasting Blood Glucose ;Fasting Insulin;Homeostatic Model Assessment of Insulin Resistance;Quantitative Insulin Sensitivity Check Index;Weight;Waist Circumference;Hip Circumference;Waist-to-Hip Ratio ;Body Mass Index;Alanine Aminotransferase;Aspartate Aminotransferase;Total Cholesterol;High-Density Lipoprotein Cholesterol;Low-Density Lipoprotein Cholesterol;Triglycerides;

Countries

China

Contacts

Public ContactXueying He

China Institute of Sport and Health Science

xueyingh1@bsu.edu.cn+86 159 0702 6071

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 1, 2026